The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE
European Journal of Nuclear Medicine and Molecular Imaging · 2024
DOI: 10.1007/s00259-024-06863-y ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Marco Maccauro und 14 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide, Pancreatic Neoplasms, Organometallic Compounds. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: In Peptide Receptor Radionuclide Therapy (PRRT) with [177Lu]Lu-DOTATATE of gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) a question remains open about the potential benefits of personalised dosimetry. This observational prospective study examines the association of individualized dosimetry with progression free survival (PFS) in G1-G2 GEP NETs patients following the standard [177Lu]Lu-DOTATATE therapeutic regimen. METHODS: The analysis was conducted on 42 patients administered 4 times, and on 165 lesions. Dosimetry was performed after the first and the forth cycle, with two SPECT/CT scans at day 1 and 7 after administration. Global mean Tumour absorbed Dose of each patient (GTD) was calculated after cycle 1 and 4 as the sum of lesion doses weighted by lesion mass, normalized by the global tumour mass. Cumulative GTD_TOT was calculated as the mean between cycle 1 (GTD_1) and 4 (GTD_4) multiplied by 4. Patients were followed-up for median 32.8 (range 18-45.5) months, through blood tests and contrast enhanced CT (ceCT). This study assessed the correlation between global tumour dose (GTD) and PFS longer or shorter than 24 months. After a ROC analysis, we stratified patients according to the best cut-off value for two additional statistical analyses. At last a multivariate analysis was carried out for PFS > / / 24 months as a function of GTD_1. DISCUSSION: Several statistical analyses seem to confirm that simple tumour dosimetry with 2 SPECT/CT scans after the first administration allows to predict PFS values after 4 × 7.4 GBq administrations of 177Lu[Lu]-DOTATATE in G1-G2 GEP NETs. This result qualitatively confirms recent findings by a Belgian and a French study. However, dosimetric thresholds are different. This probably comes from different cohort baseline characteristics, since the median PFS in our study (42 m) was longer than in the other studies (28 m and 31 m). CONCLUSION: Tumour dosimetry after the first administration of [177Lu]Lu-DOTATATE offers an important prognostic value in the clinical decision-making process, especially for the future as alternative emitters or administration schedule may become available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
- Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
- Department of Health Sciences (DISSAL), University of Genova, Genoa, Italy.
- Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
- Radiology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
ORCID-Profile: Marco Maccauro, Matteo Bauckneht, Matteo Bagnalasta, Federica Scalorbi, Margarita Kirienko, Carlo Chiesa
Zitieren
APA
Maccauro, M., Cuomo, M., Bauckneht, M., Bagnalasta, M., Mazzaglia, S., Scalorbi, F., Argiroffi, G., Kirienko, M., Lorenzoni, A., Aliberti, G., Pusceddu, S., Giuseppina, C., Garanzini, E. M., Seregni, E., & Chiesa, C. (2024). The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06863-y
Vancouver
Maccauro M, Cuomo M, Bauckneht M, Bagnalasta M, Mazzaglia S, Scalorbi F, et al. The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06863-y
BibTeX
@article{Maccauro2024,
author = {Maccauro, Marco and Cuomo, Mariarosaria and Bauckneht, Matteo and Bagnalasta, Matteo and Mazzaglia, Stefania and Scalorbi, Federica and Argiroffi, Giovanni and Kirienko, Margarita and Lorenzoni, Alice and Aliberti, Gianluca and Pusceddu, Sara and Giuseppina, Calareso and Garanzini, Enrico Matteo and Seregni, Ettore and Chiesa, Carlo},
title = {The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
doi = {10.1007/s00259-024-06863-y}
}
EUVIMED